Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
AstraZeneca
Scientific Title
A Phase III, Open-label, Randomized Study of Osimertinib With or Without Platinum Plus Pemetrexed Chemotherapy, as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation Positive, Locally Advanced Non-Small Cell Lung Cancer